Immune Repertoire of Ovarian HGSC
Differential Expression of Immune Repertoire of T/B Lymphocytes in Ovarian High Grade Serous Carcinoma
1 other identifier
observational
40
1 country
1
Brief Summary
In this preliminary study, peripheral blood and carcinoma tissue with pericarcinomatous tissue are taken from the patients with ovarian high grade serous carcinoma at several points: before any treatment, after the debulking surgery, and after all the proposed chemotherapy. The differential expression of the T/B lymphocyte receptors in these samples will be analyzed with the platinum-based treatment and survival outcomes of the patients. The primary objective is the expression rates of T/B lymphocyte receptors in different stages of checking points.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 3, 2019
CompletedStudy Start
First participant enrolled
January 3, 2019
CompletedFirst Posted
Study publicly available on registry
January 4, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2022
CompletedJanuary 4, 2019
January 1, 2019
2 years
January 3, 2019
January 3, 2019
Conditions
Outcome Measures
Primary Outcomes (2)
Expression rates of T lymphocyte receptors
Expression rates of T lymphocyte receptors in different stages of checking points, including timings before any treatment, after the debulking surgery, and after all the proposed chemotherapy
One year
Expression rates of B lymphocyte receptors
Expression rates of T lymphocyte receptors in different stages of checking points, including timings before any treatment, after the debulking surgery, and after all the proposed chemotherapy
One year
Interventions
The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.
Eligibility Criteria
Patients confirmed of primary ovarian high grade serous carcinoma, aged 18 years or older and accept systematic treatment including debulking surgery and platinum-based chemotherapy.
You may qualify if:
- Confirmed of primary ovarian high grade serous carcinoma
- Aged 18 years or older
- No immunosuppressive disease
- Signed an approved informed consents
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Lei Lilead
Study Sites (1)
Lei Li
Beijing, Beijing Municipality, 100730, China
Biospecimen
Peripheral blood and carcinoma tissue with pericarcinomatous tissue are taken from the patients with ovarian high grade serous carcinoma
MeSH Terms
Interventions
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 3, 2019
First Posted
January 4, 2019
Study Start
January 3, 2019
Primary Completion
January 1, 2021
Study Completion
January 1, 2022
Last Updated
January 4, 2019
Record last verified: 2019-01